Ämnen: Haelso-sjukvaard

ELOXATIN™ (Oxaliplatin for injection) receives FDA Approval for the treatment of colon cancer following surgery

8 November 2004 10:11

~ First Major Advance in the Postsurgical Treatment Of Early-Stage Colon Cancer in More Than a Decade ~ Sanofi-Synthelabo, a member of the sanofi-aventis Group announced today that the US Food and Drug Administration (FDA) has approved ELOXATIN™, in combination with conventional chemotherapy (infusional 5-fluorouracil/leucovorin, known as 5-FU/LV), for the adjuvant (postsurgical) treatment of

European Union Approval for Taxotere® (docetaxel) in Prostate Cancer

4 November 2004 12:06

Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere®(docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen independent (hormone-refractory) metastatic prostate cancer. The Commission approval is based on the results of a large landmark phase III clinical trial, TAX 327, which demonst

Alfuzosin 10 mg OD (Xatral® OD) visar positiv effekt hos patienter med urinstopp

6 April 2004 10:31

Behovet av BPH-relaterad kirurgi reduceras Resultaten av ALFAUR-studien (ALFuzosin in Acute Urinary Retention), som presenterades vid European Association of Urologys (EAU) kongress i Wien, visar att den uroselektiva alfa1-blockeraren alfuzosin 10 mg en gång dagligen (OD = once daily) kan ha en positiv effekt på behandlingen av män som lider av akut urinretention (AUR). Akut urinretention (u

Ny studie på vanlig hjärtsjukdom hos kvinnor

8 Oktober 2003 11:12

En ny studie ska ge svar på hur en vanlig form av hjärtsvikt kan behandlas. Ungefär hälften av alla patienter med hjärtsvikt har en normal sk. systolisk funktion.

Ny Sverigechef på Sanofi-Synthelabo

8 September 2003 10:52

Sanofi-Synthelabo AB har förstärkt verksamheten genom att tillsätta Tommy Olin som operativ chef.